Vesalius Therapeutics Inc.

BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more

Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab

The VC’s Pioneering Intelligence unit is experimenting with new methods, operationalizing tools, and creating companies

After plotting rapid growth, biotech cuts 43% of staff to ‘streamline’ around top priorities

Advocates pressing for more, including center of excellence

Led by former NCATS Director Christopher Austin, the company is eschewing animal models for a ‘human-based’ approach